Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.97 |
| ▸ | MEN1 | O00255 | 3/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.76 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.76 |
| ▸ | ABCG2 | Q9UNQ0 | 9/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.43 |
| ▸ | NMT2 | O60551 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cromolyn SCHEMBL8199 | 1.00 | GPR35 (0.97) | GPR35LMNATDP1MEN1KMT2A | |
| Cromolyn SCHEMBL29353205 | 0.99 | GPR35 (1.00) | GPR35LMNATDP1MEN1KMT2A | |
| Cromolyn SCHEMBL3865 | 0.99 | GPR35 (1.00) | GPR35LMNATDP1MEN1KMT2A | |
| Cromolyn SCHEMBL29352570 | 0.99 | GPR35 (1.00) | GPR35LMNATDP1MEN1KMT2A | |
| Cromolyn SCHEMBL8662365 | 0.97 | GPR35 (0.97) | GPR35LMNATDP1MEN1KMT2A | |
| Cromolyn SCHEMBL4108171 | 0.97 | GPR35 (0.97) | GPR35LMNATDP1MEN1KMT2A | |
| SCHEMBL11253121 | 0.95 | GPR35 (0.93) | GPR35LMNATDP1MEN1KMT2A | |
| SCHEMBL11832140 | 0.93 | GPR35 (0.88) | GPR35LMNATDP1MEN1KMT2A | |
| SCHEMBL11175797 | 0.93 | GPR35 (0.88) | GPR35LMNATDP1MEN1KMT2A | |
| SCHEMBL2717434 | 0.93 | GPR35 (0.88) | GPR35LMNATDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117760980-B | Glucose detection method based on lyotropic liquid crystal liquid drops | 南京邮电大学 | 2026-05-15 | — | — | CN | claimed |
| CN-117760980-A | Glucose detection method based on lyotropic liquid crystal liquid drops | 南京邮电大学 | 2024-03-26 | — | — | CN | claimed |
| CN-116889562-A | Macrophage/microglial cell in neuroinflammation related to neurodegenerative diseases | 通用医疗公司 | 2023-10-17 | — | — | CN | claimed |
| CN-116782865-A | Atomic layer deposition coated pharmaceutical packages, improved syringes and vials, e.g., for lyophilization/cold chain drugs/vaccines | SIO2医药产品公司 | 2023-09-19 | — | — | CN | claimed |
| US-20220235270-A1 | DEFECT MEDIATED LYOTROPIC NEMATIC GEL | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2022-07-28 | — | — | US | claimed |
| EP-3986979-A1 | DEFECT MEDIATED LYOTROPIC NEMATIC GEL | The University Court Of The University of Edinburgh (GB) | 2022-04-27 | — | — | EP | claimed |
| CN-113292644-A | Cytokine activity stabilizer and preparation method thereof | 南京艾拓生命科技有限公司 | 2021-08-24 | — | — | CN | claimed |
| CN-112274479-A | Hair growing method based on hair mother stem cells and microneedles | 弘康信达(江苏)医学研究有限公司 | 2021-01-29 | — | — | CN | claimed |
| WO-2020254813-A1 | DEFECT MEDIATED LYOTROPIC NEMATIC GEL | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2020-12-24 | — | — | WO | claimed |
| US-20190240194-A1 | MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES | THE GENERAL HOSPITAL CORPORATION | 2019-08-08 | — | — | US | claimed |
| US-6684405-B2 | PROTECTIVE DEVICES COMPRISING ELASTOMERS HAVING COATING MIXTURES OF CROMOLYN'S, ENZYME INHIBITORS SELECTED FROM ANTITRYPSIN, MACROBLOBULIN OR SECRETORY LEUCOCYTE PROTEASE INHIBITORS AS VIRICIDES AND ANTIALLERGENS | LEZDEY JOHN (US) | 2004-02-03 | — | — | US | claimed |
| EP-1322595-A2 | (5-(2-HYDROXY-4-CHLOROBENZOYL) AMINOVALERIC ACID AND SALTS THEREOF AND COMPOSITIONS CONTAINING THE SAME FOR DELIVERING ACTIVE AGENTS | Emisphere Technologies, Inc. (US) | 2003-07-02 | — | — | EP | claimed |
| US-6573249-B2 | A formulation for healing burns and wounds in mammals, which contains a cromolyn sodium or disodium salt or the combination of cromolyn salt and hyaluronic acid in suitable carrier | ALPHAMED PHARMACEUTICAL CORP. | 2003-06-03 | — | — | US | claimed |
| US-6511960-B2 | Cromolyn for eye and ear infections | ALPHAMED PHARMACEUTICALS CORP | 2003-01-28 | — | — | US | claimed |
| US-20020189001-A1 | Surgical and examination gloves | LEZDEY JOHN (US) | 2002-12-19 | — | — | US | claimed |
| US-6468557-B1 | HERPES SIMPLEX VIRUS (HSV) OR HUMAN PAPILLOMA VIRUS (HPV); CROMOLYN COMPOUND | ALPHAMED PHARMACEUTICAL CORP. | 2002-10-22 | — | — | US | claimed |
| US-20020091100-A1 | Cromolyn for eye and ear infections | ALPHAMED PHARMACEUTICALS CORPORATION | 2002-07-11 | — | — | US | claimed |
| US-6379684-B1 | Cosmetic compositions containing cromolyn compounds for revitalizing the skin | ALPHAMED PHARACEUTICAL CORP. | 2002-04-30 | — | — | US | claimed |
| WO-2002019969-A2 | (5-(2-HYDROXY-4-CHLOROBENZOYL) AMINOVALERIC ACID AND SALTS THEREOF AND COMPOSITIONS CONTAINING THE SAME FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES INC. (US) | 2002-03-14 | — | — | WO | claimed |
| US-20010041684-A1 | Topical wound therapeutic compositions | LEZDEY JOHN (US) | 2001-11-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240194-A1 | MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES | CD68, PRNP, HTT | GPR35 1528/4885LMNA 755/4885TDP1 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.